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The incidence of bronchiectasis has probably declined in developed countries in recent years, but no 
reliable statistical data on this are available. The present paper describes the use made of hospital services 
by bronchiectatic patients in Finland. Data on a total of 12 539 treatment periods for bronchiectasis that 
had occurred between 1972 and 1992 were collected from the discharge register maintained by the 
National Research and Development Centre for Welfare and Health (diagnosis 518 in the International 
Classification of Diseases up to 1986, and 494 from 1987 onwards). The number of admissions, new 
occurrences of bronchiectasis and days in hospital were calculated by sex and age in relation to the total 
population at the end of each year. There were 143 and 87 admissions per million inhabitants in 1972 and 
1992, respectively. The admissions, new occurrences and the days in hospital all decreased, at annual 
rates of 1.3, 4.2 and 5.7%, respectively. Thus, where the number of new occurrences was 50 per million 
persons in 1977, it was 27 per million in 1992. In summary, bronchiectasis-related hospital treatment 
declined markedly between 1972 and 1992. Trend is attributed to effective treatment of pulmonary 
infections and the reduction in tuberculosis. 
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Introduction 
Bronchiectasis is defined as an abnormal and irrevers- 
ible dilation of one or more bronchi. The spectrum 
of presumed causes includes inhalation of toxic sub- 
stances, severe childhood respiratory infection, aspi- 
ration, humoral antibody deficiency, mucociliary 
dysfunction, cystic fibrosis and allergic bronchopul- 
monary disease, in addition to cases of unknown 
aetiology (1). 
The Finnish National Research and Development 
Centre for Welfare and Health maintains a register of 
all patients discharged from hospital since 1967, 
which is extended by about 1.2 million new entries 
annually. This provides a good basis for studying 
bronchiectasis-related hospital treatment in Finland. 
The aim of the present investigation was to describe 
trends in the use made of hospital services by bron- 
chiectatic patients, in order to try to evaluate the 
present clinical importance of this disease. 
The prevalence of bronchiectasis in the 1950s in 
England was estimated to be from 1.3 to 1.5 cases per 
thousand (2,3), and the incidence among children 
in the 1960s was reported to be 1.06 per 10 000 (4). 
Despite the lack of subsequent data, it is assumed 
that the incidence and prevalence have decreased in 
recent decades (5). However, this is not the case in the 
developing countries, where bronchiectasis remains a 
common problem (6,7). 
Methods 
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The National Research and Development Centre for 
Welfare and Health is provided with registration data 
of all patients treated in hospitals in Finland, includ- 
ing their diagnoses. All treatment periods for which 
the main diagnosis was bronchiectasis [diagnosis 5 18, 
International Classification of Diseases (ICD), eighth 
revision, up to 1986 and diagnosis 494, ICD, ninth 
revision, from 19871 were collected from the register, 
including diagnostic visits, acute exacerbation stages 
and check-up visits. A total of 12 539 bronchiectasis- 
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related treatment periods were recorded between 1972 
and 1992, and the numbers of admissions, new occur- 
rences of bronchiectasis and days spent in hospital 
were calculated by sex and age in relation to the total 
population at the end of each year. The population 
data were based on information provided by the 
Central Statistical Office of Finland. There were 
4.7 million inhabitants in Finland in 1972, rising to 
5.1 million by 1992. 
A bronchiectatic patient who had had no recorded 
bronchiectasis-related hospital treatment periods 
between 1972 and 1976, and was first treated in 
hospital in 1977 or later, was considered to be a new 
patient. 
All hospital treatment days were counted as days in 
hospital, the days of arrival and departure making up 
1 day. If the duration of treatment exceeded 365 days, 
these days were excluded from the analysis. There 
were a total of 22 treatment periods of such duration 
during the investigation period. The average dura- 
tion of stay in hospital was calculated by dividing 
the number of days in hospital by the number of 
treatment periods. 
The relative rate of change was calculated by linear 
regression on the natural logarithm of the rate of 
hospital admissions, days in hospital and new occur- 
rences of bronchiectasis per million persons per year 
(8). The percentage change per year is equivalent to 
lOO($ - 1). The statistical analyses were performed 
with the SPSS 6.1 for Windows program. 
Results 
TREATMENT PERIODS 
Bronchiectasis-related treatment periods in hospitals 
amounted to 664 in 1972 (143 treatment periods per 
million inhabitants) and 439 in 1992 (87 per million 
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FIG. 1. ‘Bronchiectasis-related rates of admission to 
hospital per million persons for Finnish males 
(+-) and females (- - -) from 1972 to 1992. 
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FIG. 2. Occurrence of new bronchiectasis cases per 
million persons among Finnish males ( --) and 
females (---) from 1977 to 1992. 
inhabitants) (Fig. 1). The annual change in the 
number of such periods was - 1.3% [95% confidence 
interval (95% CI) - 2.6 to - 0.11. Forty-five percent 
of all treatment periods were for males. 
NEW TREATMENT PERIODS 
A total of 3457 new treatment periods occurred 
between 1977 and 1992, with 238 in 1977 and 135 in 
1992, i.e. 50 per million in 1972 vs. 27 per million 
(Fig. 2). The annual change during this 16-yr period 
was - 4.2% (95% CI - 5.4 to - 2.9). Forty-five 
percent of all new treatment periods were for males. 
DAYS IN HOSPITAL AND AVERAGE 
DURATION OF STAY IN HOSPITAL 
The total number of bronchiectasis-related days in 
hospital during this 21-yr period was 152 101, the 
figures being equivalent to 2716 hospital days per 
million inhabitants in 1972 and 611 per million in 
1992. The days in hospital changed by an average of 
- 5.7% (95% CI - 6.9 to - 4.5). The average dura- 
tion of stay in hospital decreased during the 21-yr 
period, from 19.0 days in 1972 to 7.0 days in 1992. 
Discussion 
The discharge register maintained by the National 
Research and Development Centre for Welfare and 
Health is an extensive one, covering all private, 
public, general and mental hospitals in Finland. The 
correspondence between its diagnosis data and 
patient records has been found to be good, as high as 
95% (9). Of the new cases of bronchiectasis, 78% were 
diagnosed in pulmonary departments, mostly con- 
firmed by bronchography. High-resolution computed 
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tomography (HRCT) began in Finland in 1989 and 
was gradually introduced for diagnosing bronchi- 
ectasis, firstly in the university clinics in the early 
1990s. Even now, HRCT is rare in Finnish central 
hospitals. It is very sensitive, although it may miss 
cases of cylindrical bronchiectasis (10). Thus, in 
the present study, bronchiectasis means hospital 
diagnosis made without HRCT. 
The ICD classification changed in 1987 between 
the eight and ninth revisions, but this is unlikely to 
have had much influence on the results concerned 
here. It was found in research into chronic obstructive 
pulmonary disease (COPD), for instance, that the 
changes that occurred progressively from the sixth 
revision to the ninth had only a minimal effect on the 
trend in COPD mortality (11). 
The number of bronchiectasis-related hospital 
treatment periods, the number of days spent in hos- 
pital and the average stay in hospital all decreased 
during the study period. Svartengren et al., in one 
of the few investigations into hospital treatment 
provided for bronchiectatic patients in Western 
countries, found 771 patients with a diagnosis of 
bronchiectasis having at least one hospital stay in a 
register covering all the patients who had been in 
hospital in the administrative district of Stockholm 
(1.5 million inhabitants) between 1969 and 1978 (12). 
The reduction in bronchiectasis-related hospital 
treatment may be attributed to a number of putative 
factors: early, effective treatment of necrotizing pneu- 
monia, control of tuberculosis and the prevention of 
predisposing pulmonary infections by routine immu- 
nization. There was a sharp fall in the incidence 
of cases of bronchiectasis at children’s hospitals in 
England between 1950 and 1960, coinciding with the 
time when broad spectrum antibiotics were intro- 
duced (13). The annual incidence of new cases of 
tuberculosis in Finland has declined markedly during 
this period on account of the availability of new 
medication. There were 93.7 new cases of tuberculosis 
per 100 000 persons in 1972, but only 13.8 per 100 000 
persons in 1992. The introduction of effective vacci- 
nation programmes has almost eradicated measles 
and reduced the cases of whooping cough in Finland, 
and the health care system has also become more 
effective in reducing the rates of bronchiectasis and 
shortening the duration of stays in hospital. 
The decline in the number of new cases of bron- 
chiectasis during the 16-yr period provides perhaps 
the clearest evidence that the disease is really decreas- 
ing, since these reflect the incidence of the disease, 
which was at least 27 per million persons in 1992, 
bearing in mind the mild cases that are not seen 
in this material because they are not treated in 
hospitals. This is much less than in the 1960s (4). 
Thus, bronchiectasis is rare, and even in the Finnish 
population of 5 million, few new cases were found. 
The peak in the rate of admissions and days in 
hospital in 1979 may be partly attributable to the 
creation of a national asthma treatment programme, 
which probably increased the number of asthma cases 
(14) and aroused interest in research and treatment 
connected with other pulmonary disease. Thus, more 
cases of bronchiectasis were found than usual. 
Although tuberculosis of the respiratory organs is 
on the decline in Finland, atypical respiratory myco- 
bacterial diseases are apparently increasing. It is 
known that bronchiectatic patients often have atypi- 
cal mycobacterial diseases, and there is evidence that 
bronchiectasis is not merely a pre-existing condition 
but can result from atypical mycobacterial infection 
(15). The existence of such infections may increase the 
rate of bronchiectasis in the future. Cystic fibrosis is 
one significant condition predisposing patients to 
bronchiectasis. However, although it is the most 
common genetic disorder in Caucasian populations 
and is common in many Western countries, it is rare 
in Finland. 
In summary, bronchiectasis-related treatment peri- 
ods, new treatment periods, days in hospital and the 
average duration of stay in hospital declined mark- 
edly between 1972 and 1992. This may be attributed 
to the effective treatment of pulmonary infections and 
the reduction in tuberculosis, and the trend is likely to 
continue. 
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